News from AACR 2024: Wednesday’s highlights
Drug Discovery World
APRIL 11, 2024
In clonogenic assay, BRCA2-deficient DLD1 cells were ~15-fold more sensitive to FEN1 inhibition than their isogenic BRCA2-wild-type counterparts (EC50 of 350nM and 5µM, respectively), confirming the increased susceptibility of HR deficient cancer cells to FEN1 inhibition. LAE119 is a potent and selective PARP1 inhibitor and PARP1-DNA trapper.
Let's personalize your content